Virulence Factors of Chlamydiae

衣原体的毒力因子

基本信息

  • 批准号:
    7196436
  • 负责人:
  • 金额:
    $ 41.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1995
  • 资助国家:
    美国
  • 起止时间:
    1995-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chlamydia trachomatis serovars D-K are the most common cause, in the USA and worldwide, of bacterially acquired sexually transmitted diseases and their sequelae, including prostatitis, epididymitis, pelvic inflammatory disease, ectopic pregnancy and sterility. Chlamydial diseases are insidious and they constitute significant primary, secondary and tertiary health concerns in which women bear a special burden because of increased risk of adverse reproductive consequences. The goal of our laboratory for 25 years has been to try to understand the basic biology of Chlamydial growth in its host epithelial cell in order to understand the infectious process and to permit dissection of the cellular/molecular consequences of persistent infection, since the majority of Chlamydial tubal disease appears to result from subclinical, persistent infection. This proposal is a continuation of on-going efforts to understand the crucial attachment steps, which are modulated by female hormones in vitro. In Specific Aim 1, we shall determine whether or not estrogen receptors (ER) are involved in serovar E attachment to human endometrial epithelial cells or, alternatively, if the estrogen-induced physiological effects on the host cell result in display of other receptors. Specific labeled-EB binding assays to ER+ cell lines will be used in addition to BiaCore, FACS, and microscopy analyses and coupled with siRNA technology to knockdown surface ER amounts to see if reduced EB binding does occur. In Specific Aim 2, we shall monitor, by microscopy and gradient vesicle isolation, mechanisms of serovar E outer membrane bleb antigen escape through the inclusion membrane as well as from inclusion membrane everted vesicles and determine trafficking, including endoplasmic reticulum membrane fusion potential for MHC Class I loading. Finally, for Specific Aim 3, we have isolated Chlamydial projections (small scale) and, after bulk collection and generation of antibodies, plan to characterize these surface structures; the obvious question is whether or not the projections are the Chlamydial Type III secretion injectisome-equivalent.
描述(由申请人提供):在美国和世界范围内,沙眼衣原体血清型D-K是细菌性传播疾病及其后遗症的最常见原因,包括前列腺炎、附睾炎、盆腔炎、异位妊娠和不孕症。衣原体疾病具有隐蔽性,它们构成了重大的初级、二级和三级健康问题,妇女因其不利生殖后果的风险增加而承受着特别的负担。我们实验室25年来的目标一直是试图了解衣原体在其宿主上皮细胞中生长的基本生物学,以了解感染过程,并允许解剖持续感染的细胞/分子后果,因为大多数衣原体输卵管疾病似乎是由亚临床持续感染引起的。这一建议是持续不断的努力,以了解关键的依恋步骤,这是由体外雌性激素调节的。在Specific Aim 1中,我们将确定雌激素受体(ER)是否参与血清E附着于人子宫内膜上皮细胞,或者,雌激素诱导的宿主细胞生理效应是否导致其他受体的显示。除了BiaCore、FACS和显微镜分析外,还将使用ER+细胞系的特异性标记EB结合试验,并结合siRNA技术降低表面ER量,以观察EB结合是否减少。在Specific Aim 2中,我们将通过显微镜和梯度囊泡分离来监测血清型E外膜泡抗原通过包涵膜和从包涵膜外翻囊泡逃逸的机制,并确定运输,包括内质网膜融合电位用于MHC I类装载。最后,对于Specific Aim 3,我们分离了衣原体投影(小规模),并在大量收集和产生抗体后,计划表征这些表面结构;显而易见的问题是,这些突出物是否与III型衣原体分泌的注射体相当。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Priscilla B. Wyrick其他文献

Priscilla B. Wyrick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Priscilla B. Wyrick', 18)}}的其他基金

EFFICACY OF MICROBICIDES IN CHLAMYDIA TRACHOMATIS
杀菌剂对沙眼衣原体的功效
  • 批准号:
    6352614
  • 财政年份:
    2000
  • 资助金额:
    $ 41.27万
  • 项目类别:
EVALUATION OF C31G VS NONOXYNOL-9 AS TOPICAL MICROBICIDES
C31G 与 NONOXYNOL-9 作为外用杀菌剂的评价
  • 批准号:
    6099894
  • 财政年份:
    1998
  • 资助金额:
    $ 41.27万
  • 项目类别:
STUDIES OF CHLAMYDIA TRACHOMATIS
沙眼衣原体的研究
  • 批准号:
    6099529
  • 财政年份:
    1998
  • 资助金额:
    $ 41.27万
  • 项目类别:
EVALUATION OF C31G VS NONOXYNOL-9 AS TOPICAL MICROBICIDES
C31G 与 NONOXYNOL-9 作为外用杀菌剂的评价
  • 批准号:
    6235313
  • 财政年份:
    1997
  • 资助金额:
    $ 41.27万
  • 项目类别:
STUDIES OF CHLAMYDIA TRACHOMATIS
沙眼衣原体的研究
  • 批准号:
    6235018
  • 财政年份:
    1997
  • 资助金额:
    $ 41.27万
  • 项目类别:
VIRULENCE FACTORS OF CHLAMYDIAE
衣原体的毒力因子
  • 批准号:
    2059974
  • 财政年份:
    1995
  • 资助金额:
    $ 41.27万
  • 项目类别:
EFFICACY OF MICROBICIDES IN CHLAMYDIA TRACHOMATIS
杀菌剂对沙眼衣原体的功效
  • 批准号:
    6233362
  • 财政年份:
    1995
  • 资助金额:
    $ 41.27万
  • 项目类别:
VIRULENCE FACTORS OF CHLAMYDIAE
衣原体的毒力因子
  • 批准号:
    6372959
  • 财政年份:
    1995
  • 资助金额:
    $ 41.27万
  • 项目类别:
Virulence Factors of Chlamydiae
衣原体的毒力因子
  • 批准号:
    6913865
  • 财政年份:
    1995
  • 资助金额:
    $ 41.27万
  • 项目类别:
Virulence Factors of Chlamydiae
衣原体的毒力因子
  • 批准号:
    7588794
  • 财政年份:
    1995
  • 资助金额:
    $ 41.27万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 41.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了